IL10 and colitis: Elucidating the exact upstream mechanism by which IL-10 restrains VLC ceramide accumulation may also aid in refining recombinant IL-10 therapies that have been tested in the clinic for colitis but ultimately failed to meet their endpoints due to lack of precision and efficacy.